Illumina, Inc. $ILMN Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. has reduced its stake in Illumina, Inc. by 38.6% in the first quarter, selling 51,741 shares and now owning 82,131 shares valued at approximately $6.5 million.
• Illumina reported a year-over-year revenue decline of 4.8% with quarterly earnings of $1.19 per share, exceeding analyst expectations of $1.02.
• Several research analysts have differentiated views on Illumina, with target prices ranging from $85.00 to $125.00, indicating a mix of ratings including seven "Buy," eleven "Hold," and two "Sell."

Candriam S.C.A. decreased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 38.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,131 shares of the life sciences company's stock after selling 51,741 shares during the quarter. Candriam S.C.A. owned 0.05% of Illumina worth $6,516,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Fourth Dimension Wealth LLC acquired a new position in Illumina during the 4th quarter worth $40,000. Rakuten Securities Inc. raised its position in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. purchased a new position in shares of Illumina during the first quarter valued at $33,000. PFS Partners LLC grew its holdings in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after buying an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its holdings in shares of Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after buying an additional 292 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Price Performance

NASDAQ ILMN opened at $99.29 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $15.26 billion, a PE ratio of 12.57, a P/E/G ratio of 2.27 and a beta of 1.37. The stock has a 50-day simple moving average of $97.88 and a 200 day simple moving average of $89.28.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the company earned $0.36 EPS. The company's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a research note on Friday, July 11th. Canaccord Genuity Group upped their price target on Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research note on Friday, August 1st. JPMorgan Chase & Co. decreased their price target on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Guggenheim decreased their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Monday, August 4th. Seven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina has an average rating of "Hold" and an average target price of $124.58.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.